%22%2F%3E%0A%3Cdefs%3E%0A%3CradialGradient%20id%3D%22paint0_radial_53404_20784%22%20cx%3D%220%22%20cy%3D%220%22%20r%3D%221%22%20gradientUnits%3D%22userSpaceOnUse%22%20gradientTransform%3D%22translate(11.6786%2037.1765)%20scale(40.1126%2040.1123)%22%3E%0A%3Cstop%20stop-color%3D%22%23B4C9EA%22%2F%3E%0A%3Cstop%20offset%3D%221%22%20stop-color%3D%22%23426BBA%22%2F%3E%0A%3C%2FradialGradient%3E%0A%3C%2Fdefs%3E%0A%3C%2Fsvg%3E%0A)
Featured Trial
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
In Partnership With:
Study Identifier:
SEP361-226
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
N/A
Study Contact Information:
Type
Interventional
Phase
Phase 2
Estimated Enrollment
434
Trial Dates
Mar 2023 - Feb 2025
Study Drug
Therapeutic Area
Trial Locations
Location
Status
Location
University of Alabama at Birmingham Site #116
Huntsville, Alabama, United States, 35801
Status
Recruiting
Location
Excell Research, Inc. Site #106
Oceanside, California, United States, 92056
Status
Recruiting
Location
Viking Pharmaceutical Trials Inc. dba Viking Clinical Research Site#110
Temecula, California, United States, 92591
Status
Recruiting
Location
CenExel Collaborative Neuroscience Research Site #113
Torrance, California, United States, 90502
Status
Recruiting
Location
K2 Medical Research, LLC Site #114
Tampa, Florida, United States, 33607
Status
Recruiting
Location
NeuroTrials Research, Inc. Site #103
Atlanta, Georgia, United States, 30328
Status
Active, not recruiting